Delivery Order SPE2DB25D3108-SPE2DB26FPBNK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,957.42 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order, with a firm fixed price structure, represents a child contract against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $21,156.80 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This non-set-aside contract, which is due for completion by November 4, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,548.41 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on October 21, 2025, with an ultimate completion date of October 22, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a $48,029.65 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on April 30, 2025, with completion scheduled for May 1, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,840.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed price, competitively awarded delivery order was issued on October 20, 2025, with an ultimate completion date of October 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed-price contract, with an ultimate completion date of September 24, 2025, is a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $24,451.87 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order carries a firm fixed price and is scheduled for completion by September 8, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $3,577.74. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement. The award will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is a child contract under AmerisourceBergen...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB26FPBNKDelivery Order
The Defense Logistics Agency (DLA) awarded a $10,274.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract, with an ultimate completion date of November 5, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation, and the product will be delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical vendor supplying pharmaceuticals and medical supplies primarily to military and veteran healthcare systems. This delivery order for Dupixent, a specialty pharmaceutical treatment, exemplifies the company's role as a comprehensive pharmaceutical prime vendor under the DLA's global pharmaceutical support program, which provides essential medications and medical commodities across multiple therapeutic domains to Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 11/4/25 |